Clinical trials: Fungal Disease
Bacterial Infections
Experimental Phage Therapy of Bacterial Infections
The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive…
- Trial name
- NCT00945087
- Testing
- Bacteriophage preparation
- Where
- Poland
- Sponsor
- Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
Acute Myeloid Leukemia
Intermittent Liposomal Amphotericin B Primary Prophylaxis
The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when used as a preventer against invasive fungal infection in patients with acute leukaemia who are undergoing chemotherapy.
- Trial name
- NCT00451711
- Testing
- Liposomal amphotericin B
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Bayside Health
Meningitis, Meningococcal
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
This Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study was conducted to assess the immunogenicity and safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W)…
- Trial name
- NCT03205371
- Testing
- MenACYW conjugate vaccine, MMR, Varicella
- Where
- 37 sites in Mexico, Russia and 2 more
- Volunteers
- 1,183 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease, Meningococcal Meningitis
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent subjects who completed study V59P6 in which they received either Novartis Meningococcal (MenACWY) Conjugate Vaccine or Licensed…
- Trial name
- NCT01018732
- Testing
- Novartis Meningococcal (MenACWY-CRM) vaccine
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Ocular Histoplasmosis
Treatment for Presumed Ocular Histoplasmosis
The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.
- Trial name
- HANDLE (NCT01790893)
- Testing
- aflibercept
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- John Kitchens, MD
Dysentery, Shigella
Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
This study is an inpatient trial to determine the safety, immunogenicity and efficacy of the WRSS1 candidate vaccine in healthy Thai adult volunteers.
- Conditions
- Dysentery, Shigella, Diarrhea
- Trial name
- NCT01080716
- Testing
- Part 1/Arm 1 of Study: WRSS1 vaccine, Part 2/Arm 1 of Study: S. sonnei 53G, Part 2/Arm 2 of Study: S. sonnei 53G
- Where
- Thailand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Failure to Thrive, Infection, Bacterial
High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children
High calorie formula (Oral Nutrition Supplement/ONS) are products used for oral nutrition support with the aim to increase the nutritional intake. they are a nutrition treatment option children with limited intake.
- Conditions
- Failure to Thrive, Infection, Bacterial, Growth Faltering
- Trial name
- NCT05333133
- Testing
- high calorie formula (oral nutritional supplement/ONS)
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Universitas Airlangga
Coccidioidomycosis, Pneumonia
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
This is an observational study in 750 individuals aged 14 years or older, diagnosed with Community Acquired Pneumonia (CAP) who meet all eligibility criteria in Coccidioides endemic regions.
- Trial name
- NCT03908632
- Where
- 6 sites in United States
- Volunteers
- 651 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Infection, Invasive Pulmonary Aspergillosis
Early Diagnosis of Invasive Lung Aspergillosis
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in…
- Trial name
- NCT05860387
- Testing
- Next generation improvement of early invasive aspergillosis
- Where
- 7 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Tuberculosis, Latent Tuberculosis
Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda
Mycobacterium tuberculosis (Mtb) is a major human pathogen, responsible for an estimated 10.6 million cases of active tuberculosis (TB) and 1.6 million deaths in 2021.
- Trial name
- MICRO-LTBI_UG (NCT06751706)
- Where
- Uganda
- Volunteers
- 60 people
- Sponsor
- Queen Mary University of London
Bacterial Infections
Diagnostic Evaluation Study of the BactInsight Blood Culture System in West-Africa
Diagnosis of bloodstream infections (BSI) is done by sampling blood in blood culture bottles that are checked for growth in the microbiology laboratory.
- Trial name
- SIMBLE-FIELD (NCT05722184)
- Testing
- BactInsight blood culture system
- Where
- 2 sites in Benin
- Volunteers
- 1,724 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Sepsis, Sepsis Bacterial
Molecular Culture for the Diagnosis of Pediatric Sepsis
Babies and children have an increased risk of getting an infection with a bacteria in the bloodstream (sepsis). It is often difficult for the doctor to determine whether a child has an infection of the bloodstream, because the…
- Conditions
- Sepsis, Sepsis Bacterial, Sepsis, Neonatal, Infection, Bacterial
- Trial name
- CHAMPIONS (NCT06018792)
- Testing
- Molecular Culture
- Where
- 2 sites in Netherlands
- Volunteers
- 1,835 people
- Sponsor
- Jip Groen
Bacterial Vaginosis
Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis
To investigate the efficacy (therapeutic response) of Gynevac vaccination following a 5-shot treatment period in patients with bacterial vaginosis, based on the Nugent Score and the Amsel criteria
- Trial name
- NCT02173184
- Testing
- Gynevac
- Where
- 8 sites in Hungary
- Volunteers
- 240 people
- Sponsor
- Amvac Kft.
Hemifacial Microsomia, Mucormycosis
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects.
- Conditions
- Hemifacial Microsomia, Mucormycosis, Oral Squamous Cell Carcinoma, Microgenia
- Trial name
- 3DFACE (NCT07654647)
- Testing
- Patient-specific titanium implants for facial reconstruction
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Latakia University
Atypical Mycobacterium Infection
Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections
This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in fighting severe infectious (other than tuberculosis) caused by a group of bacteria called mycobacteria.
- Trial name
- NCT00001911
- Testing
- Interleukin-12
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071084
- Testing
- HuMax-CD4
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Genmab
Neisseria Gonorrheae Infection
Performance, Acceptability, and Usability of a Novel Rapid Lateral Flow Test for Detecting Neisseria Gonorrhoeae in Pregnant and Symptomatic Women Attending Clinics in South Africa.
Previous studies of the Neisseria gonorrhoeae (NG) lateral flow assay (LFA) have shown promising results. In East London, South Africa, the LFA demonstrated a sensitivity of 80% in asymptomatic women.
- Trial name
- GO-SA (NCT07530406)
- Testing
- Novel Lateral Flow Assay for Neisseria gonorrhoeae
- Where
- South Africa
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- Foundation for Professional Development (Pty) Ltd
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
Disseminated infection with Mycobacteria avium complex (MAC) is one of the most common systemic bacterial infections in advanced stages of the acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT00001763
- Testing
- Interleukin-12
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
Escherichia coli is the primary cause of urinary tract infections and Gram-negative bacteremia worldwide. Since the early years of the 21st century, E.coli has acquired a new mechanism of resistance to antibiotics: extended…
- Trial name
- FOXICOLI (NCT01820793)
- Testing
- Cefoxitin
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.